| Literature DB >> 25436236 |
Xin Yue Chan1, Kah Ooi Chua1, Kah Yan How1, Wai-Fong Yin1, Kok-Gan Chan1.
Abstract
Most Pseudomonas putida strains are environmental microorganisms exhibiting a wide range of metabolic capability but certain strains have been reported as rare opportunistic pathogens and some emerged as multidrug resistant P. putida. This study aimed to assess the drug resistance profile of, via whole genome analysis, P. putida strain T2-2 isolated from oral cavity. At the same time, we also compared the nonenvironmental strain with environmentally isolated P. putida. In silico comparative genome analysis with available reference strains of P. putida shows that T2-2 has lesser gene counts on carbohydrate and aromatic compounds metabolisms, which suggested its little versatility. The detection of its edd gene also suggested T2-2's catabolism of glucose via ED pathway instead of EMP pathway. On the other hand, its drug resistance profile was observed via in silico gene prediction and most of the genes found were in agreement with drug-susceptibility testing in laboratory by automated VITEK 2. In addition, the finding of putative genes of multidrug resistance efflux pump and ATP-binding cassette transporters in this strain suggests a multidrug resistant phenotype. In summary, it is believed that multiple metabolic characteristics and drug resistance in P. putida strain T2-2 helped in its survival in human oral cavity.Entities:
Mesh:
Year: 2014 PMID: 25436236 PMCID: PMC4243125 DOI: 10.1155/2014/930727
Source DB: PubMed Journal: ScientificWorldJournal ISSN: 1537-744X
Summary of reference genome mapping of P. putida T2-2 against the complete genome of P. putida W619, P. putida HB3267, P. putida F1, and P. putida GB-1.
| Reference genome | GenBank accession number | Consensus length, (Mbp) | Average coverage | Reads map to reference genome, % | Bases map to reference genome, % |
|---|---|---|---|---|---|
|
| CP000949.1 | 5.77 | 84 | 49.51 | 50.19 |
|
| CP003738.1 | 5.88 | 158 | 61.55 | 62.11 |
|
| CP000712.1 | 5.96 | 94 | 61.51 | 62.14 |
|
| CP000926.1 | 6.08 | 142 | 62.39 | 62.99 |
Figure 1Subsystem distribution of P. putida T2-2 genome. Whole genome sequence was annotated and the subsystem distribution was generated from RAST.
Summary of T2-2 draft genome compared with other P. putida complete genomes available in RAST.
| Sample of | Genome ID in RAST | Genome size (Mbp) | Total CDSs |
|---|---|---|---|
| T2-2 | 303.65 | 5.5 | 5053 |
| F1 | 351746.4 | 6.0 | 5252 |
| GB-1 | 76869.3 | 6.1 | 5410 |
| W619 | 390235.3 | 5.8 | 5182 |
Figure 2(a) Agarose gel image for 1: 1 kb DNA ladder; 2: PCR product edd gene in P. putida T2-2; 3: PCR product edd gene in P. putida S13 which serves as positive control, and 4: negative control. (b) Dot plot from DNA sequence of edd gene of P. putida T2-2 against P. putida S13. (c) Dot plot from amino acid sequence of edd gene of P. putida T2-2 against reference gene Pseudomonas strain BAY1663.
Antibiogram of Pseudomonas putida strain T2-2. Antimicrobial compounds with MICs higher than expected were regarded as resistant by strain T2-2 and marked as “R” while the compounds with lower or equal to expected MICs were interpreted as sensitive for strain T2-2 and were marked as “S”.
| University of Malaya | |||||
| BioMerieux customer: | Laboratory report | Printed on July 31, 2014, 20:42 SGT | |||
| System number: | |||||
| Printed by labsuper | |||||
| Isolate group: t2 2-1 | |||||
| Card type: AST-GN83 Testing Instrument: 000015F14C94 (Serial No. 4058) | |||||
|
| |||||
| Organism quantity: | |||||
|
Selected organism: | |||||
|
| |||||
|
| |||||
|
| |||||
|
| |||||
|
| |||||
|
|
| ||||
|
|
July 30, 2014, 14:35 SGT | ||||
|
| |||||
|
| |||||
|
The following antibiotic(s) are suppressed from analysis: | |||||
|
| |||||
| Susceptibility information |
| AST-GN83 |
|
| April 23, 2015 |
|
| July 31, 2014, |
|
| 15.50 hours | |
|
| |||||
|
|
|
|
|
|
|
|
| |||||
| Ampicillin | >=32 | R | Ceftriaxone | 8 | S |
| Amoxicillin/clavulanic | >=32 | R | Cefepime | <=1 | S |
| Ampicillin/sulbactam | >=32 | R | Aztreonam | ||
| Piperacillin/tazobactam | 8 | S | Meropenem | 4 | S |
| Cefazolin | >=64 | R | Amikacin | <=2 | S |
| Cefuroxime | >=64 | R | Gentamicin | <=1 | S |
| Cefuroxime axetil | >=64 | R | Ciprofloxacin | 0.5 | S |
| Cefoxitin | >=64 | R | Nitrofurantoin | >=512 | R |
| Cefotaxime | 8 | S | Trimethoprim/sulfamethoxazole | >=320 | R |
| Ceftazidime | 2 | S | |||
|
| |||||
| + = deduced drug, ∗ = AES modified, and ∗∗ = user modified | |||||
|
| |||||
| AES findings: |
|
| global | ||
|
| |||||
|
| |||||
|
| |||||
|
|
|
|
| ||
|
|
|
| |||
Installed VITEK 2 systems version: 07.01.
MIC interpretation guideline: global CLSI-based. Therapeutic interpretation guideline: natural resistance.
AES parameter set name: global CLSI-based+natural resistance. AES parameter last modified: May 28, 2014, 14:17 SGT.
Figure 3Genes organization of multidrug resistance efflux pumps identified by RAST annotation of T2-2 genome. (1) RND efflux system, inner membrane transporter, CmeB; (2) membrane fusion protein of RND family multidrug efflux pump; (3) RND efflux system, outer membrane lipoprotein, CmeC; (4) transcription repressor of multidrug efflux pump acrAB operon, TetR(AcR) family.